Current evidence supports that propranolol is safe to use for otherwise healthy infants with IH

Current evidence supports that propranolol is safe to use for otherwise healthy infants with IH
Can the effect of propranolol on infantile hemangiomas be quantified? Background: The utilization of propranolol for the treatment of infantile hemangiomas is efficacious and is considered the first-line treatment. Many questions still remain regarding propranolol, including the mechanism of action, the specific clinical effects, the duration of treatment and the reason(s) for treatment failure in […]
Will propranolol become the mainstay of treatment for symptomatic infantile hemangiomas (IH)? Background: IH are the most common tumor of infancy, affecting four to 10 percent of infants. Spontaneous involution is the expected outcome, but nearly 10 percent cause symptoms warranting early therapy. Propranolol was serendipitously found to hasten IH involution, with fewer side effects […]